CN106581035A - 一种治疗干眼病的西药组合物 - Google Patents
一种治疗干眼病的西药组合物 Download PDFInfo
- Publication number
- CN106581035A CN106581035A CN201611107165.4A CN201611107165A CN106581035A CN 106581035 A CN106581035 A CN 106581035A CN 201611107165 A CN201611107165 A CN 201611107165A CN 106581035 A CN106581035 A CN 106581035A
- Authority
- CN
- China
- Prior art keywords
- parts
- western medicine
- xerophthalmia
- medicine compound
- acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 239000003814 drug Substances 0.000 title claims abstract description 35
- 208000005494 xerophthalmia Diseases 0.000 title claims abstract description 32
- 229920000881 Modified starch Polymers 0.000 claims abstract description 19
- 235000019426 modified starch Nutrition 0.000 claims abstract description 19
- XMAYWYJOQHXEEK-OZXSUGGESA-N (2R,4S)-ketoconazole Chemical compound C1CN(C(=O)C)CCN1C(C=C1)=CC=C1OC[C@@H]1O[C@@](CN2C=NC=C2)(C=2C(=CC(Cl)=CC=2)Cl)OC1 XMAYWYJOQHXEEK-OZXSUGGESA-N 0.000 claims abstract description 17
- MIJYXULNPSFWEK-GTOFXWBISA-N 3beta-hydroxyolean-12-en-28-oic acid Chemical compound C1C[C@H](O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C(O)=O)CCC(C)(C)C[C@H]5C4=CC[C@@H]3[C@]21C MIJYXULNPSFWEK-GTOFXWBISA-N 0.000 claims abstract description 17
- UHDGCWIWMRVCDJ-CCXZUQQUSA-N Cytarabine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 UHDGCWIWMRVCDJ-CCXZUQQUSA-N 0.000 claims abstract description 17
- JKLISIRFYWXLQG-UHFFFAOYSA-N Epioleonolsaeure Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C(O)=O)CCC(C)(C)CC5C4CCC3C21C JKLISIRFYWXLQG-UHFFFAOYSA-N 0.000 claims abstract description 17
- YBRJHZPWOMJYKQ-UHFFFAOYSA-N Oleanolic acid Natural products CC1(C)CC2C3=CCC4C5(C)CCC(O)C(C)(C)C5CCC4(C)C3(C)CCC2(C1)C(=O)O YBRJHZPWOMJYKQ-UHFFFAOYSA-N 0.000 claims abstract description 17
- MIJYXULNPSFWEK-UHFFFAOYSA-N Oleanolinsaeure Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C(O)=O)CCC(C)(C)CC5C4=CCC3C21C MIJYXULNPSFWEK-UHFFFAOYSA-N 0.000 claims abstract description 17
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 claims abstract description 17
- 239000001768 carboxy methyl cellulose Substances 0.000 claims abstract description 17
- PLHJDBGFXBMTGZ-WEVVVXLNSA-N furazolidone Chemical compound O1C([N+](=O)[O-])=CC=C1\C=N\N1C(=O)OCC1 PLHJDBGFXBMTGZ-WEVVVXLNSA-N 0.000 claims abstract description 17
- 229960001625 furazolidone Drugs 0.000 claims abstract description 17
- 229960004125 ketoconazole Drugs 0.000 claims abstract description 17
- 229940100243 oleanolic acid Drugs 0.000 claims abstract description 17
- HZLWUYJLOIAQFC-UHFFFAOYSA-N prosapogenin PS-A Natural products C12CC(C)(C)CCC2(C(O)=O)CCC(C2(CCC3C4(C)C)C)(C)C1=CCC2C3(C)CCC4OC1OCC(O)C(O)C1O HZLWUYJLOIAQFC-UHFFFAOYSA-N 0.000 claims abstract description 17
- QTTRZHGPGKRAFB-OOKHYKNYSA-N rimexolone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CC)(C)[C@@]1(C)C[C@@H]2O QTTRZHGPGKRAFB-OOKHYKNYSA-N 0.000 claims abstract description 17
- 229960001487 rimexolone Drugs 0.000 claims abstract description 17
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 claims abstract description 17
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 claims abstract description 17
- BTXXTMOWISPQSJ-UHFFFAOYSA-N 4,4,4-trifluorobutan-2-one Chemical compound CC(=O)CC(F)(F)F BTXXTMOWISPQSJ-UHFFFAOYSA-N 0.000 claims abstract description 16
- BQACOLQNOUYJCE-FYZZASKESA-N Abietic acid Natural products CC(C)C1=CC2=CC[C@]3(C)[C@](C)(CCC[C@@]3(C)C(=O)O)[C@H]2CC1 BQACOLQNOUYJCE-FYZZASKESA-N 0.000 claims abstract description 16
- RSWGJHLUYNHPMX-UHFFFAOYSA-N Abietic-Saeure Natural products C12CCC(C(C)C)=CC2=CCC2C1(C)CCCC2(C)C(O)=O RSWGJHLUYNHPMX-UHFFFAOYSA-N 0.000 claims abstract description 16
- 229960003174 lansoprazole Drugs 0.000 claims abstract description 15
- UIWFWZLAICURGT-UHFFFAOYSA-N 4-Methoxybenzenesulfonohydrazide Chemical compound COC1=CC=C(S(=O)(=O)NN)C=C1 UIWFWZLAICURGT-UHFFFAOYSA-N 0.000 claims abstract description 3
- 239000004368 Modified starch Substances 0.000 claims abstract description 3
- MJIHNNLFOKEZEW-UHFFFAOYSA-N lansoprazole Chemical compound CC1=C(OCC(F)(F)F)C=CN=C1CS(=O)C1=NC2=CC=CC=C2N1 MJIHNNLFOKEZEW-UHFFFAOYSA-N 0.000 claims abstract 2
- 150000001875 compounds Chemical class 0.000 claims description 29
- XOAAWQZATWQOTB-UHFFFAOYSA-N taurine Chemical compound NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 claims description 24
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 18
- LBKFGYZQBSGRHY-UHFFFAOYSA-N 3-hydroxy-4-methoxybenzoic acid Chemical compound COC1=CC=C(C(O)=O)C=C1O LBKFGYZQBSGRHY-UHFFFAOYSA-N 0.000 claims description 15
- 239000002994 raw material Substances 0.000 claims description 15
- KZJWDPNRJALLNS-VJSFXXLFSA-N sitosterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CC[C@@H](CC)C(C)C)[C@@]1(C)CC2 KZJWDPNRJALLNS-VJSFXXLFSA-N 0.000 claims description 15
- 238000002360 preparation method Methods 0.000 claims description 12
- 229960003080 taurine Drugs 0.000 claims description 12
- RDOXTESZEPMUJZ-UHFFFAOYSA-N anisole Chemical compound COC1=CC=CC=C1 RDOXTESZEPMUJZ-UHFFFAOYSA-N 0.000 claims description 11
- 229940042795 hydrazides for tuberculosis treatment Drugs 0.000 claims description 11
- VQUPQWGKORWZII-WDPYGAQVSA-N (2r,3r)-5,7-dihydroxy-2-(4-hydroxyphenyl)-3-[(2s,3r,4r,5r,6s)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxy-2,3-dihydrochromen-4-one Chemical compound O[C@@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@H]1O[C@H]1C(=O)C2=C(O)C=C(O)C=C2O[C@@H]1C1=CC=C(O)C=C1 VQUPQWGKORWZII-WDPYGAQVSA-N 0.000 claims description 10
- VQUPQWGKORWZII-UHFFFAOYSA-N Neoisoengelitin Natural products OC1C(O)C(O)C(C)OC1OC1C(=O)C2=C(O)C=C(O)C=C2OC1C1=CC=C(O)C=C1 VQUPQWGKORWZII-UHFFFAOYSA-N 0.000 claims description 10
- 239000004570 mortar (masonry) Substances 0.000 claims description 7
- 230000001954 sterilising effect Effects 0.000 claims description 7
- 239000002253 acid Substances 0.000 claims description 5
- VJRITMATACIYAF-UHFFFAOYSA-N benzenesulfonohydrazide Chemical compound NNS(=O)(=O)C1=CC=CC=C1 VJRITMATACIYAF-UHFFFAOYSA-N 0.000 claims description 3
- 150000003851 azoles Chemical class 0.000 claims 2
- MRIXVKKOHPQOFK-UHFFFAOYSA-N 4-methoxysalicylic acid Chemical class COC1=CC=C(C(O)=O)C(O)=C1 MRIXVKKOHPQOFK-UHFFFAOYSA-N 0.000 claims 1
- 239000000463 material Substances 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 8
- 238000004519 manufacturing process Methods 0.000 abstract description 3
- VWBWQPAZMNABMR-IANHLVBBSA-N Engeletin Chemical compound O[C@@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@H]1C(=O)C2=C(O)C=C(O)C=C2O[C@@H]1C1=CC=C(O)C=C1 VWBWQPAZMNABMR-IANHLVBBSA-N 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 230000000052 comparative effect Effects 0.000 description 13
- SIXIIKVOZAGHPV-UHFFFAOYSA-N lansoprazole Chemical compound CC1=C(OCC(F)(F)F)C=CN=C1CS(=O)C1=NC2=CC=C[CH]C2=N1 SIXIIKVOZAGHPV-UHFFFAOYSA-N 0.000 description 13
- 230000035807 sensation Effects 0.000 description 10
- 235000019615 sensations Nutrition 0.000 description 10
- 208000024891 symptom Diseases 0.000 description 10
- 239000000047 product Substances 0.000 description 7
- 208000002193 Pain Diseases 0.000 description 6
- 229930182470 glycoside Natural products 0.000 description 6
- 150000002338 glycosides Chemical class 0.000 description 6
- 230000028327 secretion Effects 0.000 description 6
- 206010063659 Aversion Diseases 0.000 description 5
- 241001002545 Engelhardia roxburghiana Species 0.000 description 5
- 208000003251 Pruritus Diseases 0.000 description 5
- 210000003560 epithelium corneal Anatomy 0.000 description 5
- 230000003780 keratinization Effects 0.000 description 5
- 241000283690 Bos taurus Species 0.000 description 4
- 206010034960 Photophobia Diseases 0.000 description 4
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 4
- 239000005864 Sulphur Substances 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 208000018931 inflamed eyes Diseases 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- 206010020565 Hyperaemia Diseases 0.000 description 3
- AFCARXCZXQIEQB-UHFFFAOYSA-N N-[3-oxo-3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propyl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C(CCNC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)N1CC2=C(CC1)NN=N2 AFCARXCZXQIEQB-UHFFFAOYSA-N 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 2
- AQHHHDLHHXJYJD-UHFFFAOYSA-N propranolol Chemical compound C1=CC=C2C(OCC(O)CNC(C)C)=CC=CC2=C1 AQHHHDLHHXJYJD-UHFFFAOYSA-N 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 206010054196 Affect lability Diseases 0.000 description 1
- 206010002198 Anaphylactic reaction Diseases 0.000 description 1
- DBAKFASWICGISY-BTJKTKAUSA-N Chlorpheniramine maleate Chemical compound OC(=O)\C=C/C(O)=O.C=1C=CC=NC=1C(CCN(C)C)C1=CC=C(Cl)C=C1 DBAKFASWICGISY-BTJKTKAUSA-N 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 206010010741 Conjunctivitis Diseases 0.000 description 1
- 206010013774 Dry eye Diseases 0.000 description 1
- 208000036649 Dysbacteriosis Diseases 0.000 description 1
- 208000027244 Dysbiosis Diseases 0.000 description 1
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 1
- 241000219739 Lens Species 0.000 description 1
- 229930182558 Sterol Natural products 0.000 description 1
- 230000036783 anaphylactic response Effects 0.000 description 1
- 208000003455 anaphylaxis Diseases 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 229960003291 chlorphenamine Drugs 0.000 description 1
- 239000003433 contraceptive agent Substances 0.000 description 1
- 230000002254 contraceptive effect Effects 0.000 description 1
- 210000000695 crystalline len Anatomy 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 230000007140 dysbiosis Effects 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 230000003054 hormonal effect Effects 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- 208000013441 ocular lesion Diseases 0.000 description 1
- 229960003712 propranolol Drugs 0.000 description 1
- 150000003254 radicals Chemical class 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 150000003432 sterols Chemical class 0.000 description 1
- 235000003702 sterols Nutrition 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 229940125725 tranquilizer Drugs 0.000 description 1
- 239000003204 tranquilizing agent Substances 0.000 description 1
- 230000002936 tranquilizing effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/255—Esters, e.g. nitroglycerine, selenocyanates of sulfoxy acids or sulfur analogues thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Molecular Biology (AREA)
- Emergency Medicine (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
本发明公开了一种治疗干眼病的西药组合物,由以下重量份数的原料组成:利美索龙2‑5份、黄杞苷0.2‑2份、羧甲基纤维素钠2‑5份、α变性淀粉5‑10份、阿糖胞苷1‑5份、枞酸0.5‑1份、4‑甲氧苯磺酰肼0.1‑1份、痢特灵1‑3份、酮康唑1‑3份、齐墩果酸0.5‑1份、兰索拉唑1‑5份、3‑羟基‑4‑甲氧基苯。该西药组合物对干眼病有较好的疗效;治疗周期较短,口感好,有利于患者坚持治疗;副作用小,能彻底根治,无并发症;且制备方法简单,生产成本低,降低了人们的经济压力。
Description
技术领域
本发明涉及西药制备技术领域,具体是一种治疗干眼病的西药组合物。
背景技术
干眼症是指任何原因造成的泪液质或量异常或动力学异常,导致泪膜稳定性下降,并伴有眼部不适和(或)眼表组织病变特征的多种疾病的总称。又称角结膜干燥症。常见之症状包括眼睛干涩、容易疲倦、眼痒、有异物感、痛灼热感、分泌物黏稠、怕风、畏光、对外界刺激很敏感;有时眼睛太干,基本泪液不足,反而刺激反射性泪液分泌,而造成常常流泪;较严重者眼睛会红肿、充血、角质化、角膜上皮破皮而有丝状物黏附,这种损伤日久则可造成角结膜病变,并会影响视力。
干眼症是一种慢性疾病,产生原因有以下几个方面:由于高龄、睡眠不足,精神紧张等生理原因,引起泪液质量下降;服用部分降压药及部分精神安定剂对泪膜产生有影响,如服用扑尔敏对泪膜产生有害作用,服用心得安和目前某些避孕药能减少泪液产生;环境,如所处房间干燥等,引起泪液的蒸发增加;长时间从事计算机操作,汽车驾驶,读书及其他精细作业,瞬目次数减少;由于隐形眼镜、过敏性结膜炎、大气污染、紫外线等其他原因,而引起的泪液减少,质量下降;长期使用抗菌素,菌群失调;妇女产后由于激素水平不稳定,月子用眼不当或情绪不稳大哭造成干眼。
目前对于干眼病的治疗方法有中医治疗、西医治疗及手术治疗三种,中医治疗的治疗周期较长,且口感差,患者不能长期坚持导致治疗失败;而现有的西医治疗依然存在副作用大,治标不治本、产生并发症的缺点;采用手术治疗不仅使得患者需要遭受治疗风险和痛苦,而且手术费用高,增加了人们的经济压力。
发明内容
本发明的目的在于提供一种治疗干眼病的西药组合物,以解决上述背景技术中提出的问题。
为实现上述目的,本发明提供如下技术方案:
一种治疗干眼病的西药组合物,由以下重量份数的原料组成:利美索龙2-5份、黄杞苷0.2-2份、羧甲基纤维素钠2-5份、α变性淀粉5-10份、阿糖胞苷1-5份、枞酸0.5-1份、4-甲氧苯磺酰肼0.1-1份、痢特灵1-3份、酮康唑1-3份、齐墩果酸0.5-1份、兰索拉唑1-5份、3-羟基-4-甲氧基苯甲酸0.2-1份、β-谷甾醇0.1-1份、牛磺酸2-5份、水45-85份。
作为本发明进一步的方案:由以下重量份数的原料组成:利美索龙3份、黄杞苷0.8份、羧甲基纤维素钠3份、α变性淀粉7份、阿糖胞苷3份、枞酸0.7份、4-甲氧苯磺酰肼0.4份、痢特灵2份、酮康唑2份、齐墩果酸0.7份、兰索拉唑2份、3-羟基-4-甲氧基苯甲酸0.5份、β-谷甾醇0.5份、牛磺酸3份、水50份。
一种治疗干眼病的西药组合物的制备方法,其特征在于,包括以下步骤:
(1)在无菌室里,取利美索龙、枞酸、4-甲氧苯磺酰肼、痢特灵、酮康唑、齐墩果酸、兰索拉唑、黄杞苷、羧甲基纤维素钠、3-羟基-4-甲氧基苯甲酸、阿糖胞苷、β-谷甾醇、牛磺酸,依次加入非金属研钵中;每加入一种原料研匀2-5min,避光保存备用;
(2)将步骤(1)所得物、α变性淀粉放入水中,在45-60℃温度下搅拌10-20min;
(3)将步骤(2)所得物在30-50℃温度下压制成重量为0.5-1g的片剂;
(4)将片剂在-15℃至-10℃温度下保存5-8h,即得成品。
作为本发明再进一步的方案:所述步骤(2)将步骤(1)所得物、α变性淀粉放入水中,在50℃温度下搅拌15min。
作为本发明再进一步的方案:所述步骤(3)将步骤(2)所得物在45℃温度下压制成重量为0.8g的片剂。
作为本发明再进一步的方案:所述步骤(4)将片剂在-12℃温度下保存6h,即得成品。
与现有技术相比,本发明的有益效果是:
该西药组合物对眼睛干涩、疲倦、眼痒、有异物感、痛灼热感、分泌物黏稠、怕风、畏光、对外界刺激很敏感、眼睛红肿、充血、角质化、角膜上皮破皮而有丝状物黏附症状均有较好的疗效;治疗周期较短,口感好,有利于患者坚持治疗;副作用小,能彻底根治,无并发症;且制备方法简单,生产成本低,降低了人们的经济压力。
具体实施方式
下面结合具体实施方式对本专利的技术方案作进一步详细地说明。
实施例1
一种治疗干眼病的西药组合物,由以下重量份数的原料组成:利美索龙2份、黄杞苷0.2份、羧甲基纤维素钠2份、α变性淀粉5份、阿糖胞苷1份、枞酸0.5份、4-甲氧苯磺酰肼0.1份、痢特灵1份、酮康唑1份、齐墩果酸0.5份、兰索拉唑1份、3-羟基-4-甲氧基苯甲酸0.2份、β-谷甾醇0.1份、牛磺酸2份、水45份。
一种治疗干眼病的西药组合物的制备方法,其特征在于,包括以下步骤:
(1)在无菌室里,取利美索龙、枞酸、4-甲氧苯磺酰肼、痢特灵、酮康唑、齐墩果酸、兰索拉唑、黄杞苷、羧甲基纤维素钠、3-羟基-4-甲氧基苯甲酸、阿糖胞苷、β-谷甾醇、牛磺酸,依次加入非金属研钵中;每加入一种原料研匀2min,避光保存备用;
(2)将步骤(1)所得物、α变性淀粉放入水中,在45℃温度下搅拌10min;
(3)将步骤(2)所得物在30℃温度下压制成重量为0.5g的片剂;
(4)将片剂在-15℃温度下保存5h,即得成品。
实施例2
一种治疗干眼病的西药组合物,由以下重量份数的原料组成:利美索龙5份、黄杞苷2份、羧甲基纤维素钠5份、α变性淀粉10份、阿糖胞苷5份、枞酸1份、4-甲氧苯磺酰肼1份、痢特灵3份、酮康唑3份、齐墩果酸1份、兰索拉唑5份、3-羟基-4-甲氧基苯甲酸1份、β-谷甾醇1份、牛磺酸5份、水85份。
一种治疗干眼病的西药组合物的制备方法,其特征在于,包括以下步骤:
(1)在无菌室里,取利美索龙、枞酸、4-甲氧苯磺酰肼、痢特灵、酮康唑、齐墩果酸、兰索拉唑、黄杞苷、羧甲基纤维素钠、3-羟基-4-甲氧基苯甲酸、阿糖胞苷、β-谷甾醇、牛磺酸,依次加入非金属研钵中;每加入一种原料研匀5min,避光保存备用;
(2)将步骤(1)所得物、α变性淀粉放入水中,在60℃温度下搅拌20min;
(3)将步骤(2)所得物在50℃温度下压制成重量为1g的片剂;
(4)将片剂在-10℃温度下保存8h,即得成品。
实施例3
一种治疗干眼病的西药组合物,由以下重量份数的原料组成:利美索龙3份、黄杞苷0.8份、羧甲基纤维素钠3份、α变性淀粉7份、阿糖胞苷3份、枞酸0.7份、4-甲氧苯磺酰肼0.4份、痢特灵2份、酮康唑2份、齐墩果酸0.7份、兰索拉唑2份、3-羟基-4-甲氧基苯甲酸0.5份、β-谷甾醇0.5份、牛磺酸3份、水50份。
一种治疗干眼病的西药组合物的制备方法,其特征在于,包括以下步骤:
(1)在无菌室里,取利美索龙、枞酸、4-甲氧苯磺酰肼、痢特灵、酮康唑、齐墩果酸、兰索拉唑、黄杞苷、羧甲基纤维素钠、3-羟基-4-甲氧基苯甲酸、阿糖胞苷、β-谷甾醇、牛磺酸,依次加入非金属研钵中;每加入一种原料研匀3min,避光保存备用;
(2)将步骤(1)所得物、α变性淀粉放入水中,在50℃温度下搅拌15min;
(3)将步骤(2)所得物在45℃温度下压制成重量为0.8g的片剂;
(4)将片剂在-12℃温度下保存6h,即得成品。
对比例1
一种治疗干眼病的西药组合物,由以下重量份数的原料组成:利美索龙3份、黄杞苷0.8份、羧甲基纤维素钠3份、α变性淀粉7份、阿糖胞苷3份、枞酸0.7份、4-甲氧苯磺酰肼0.4份、痢特灵2份、酮康唑2份、兰索拉唑2份、3-羟基-4-甲氧基苯甲酸0.5份、β-谷甾醇0.5份、牛磺酸3份、水50份。
一种治疗干眼病的西药组合物的制备方法,其特征在于,包括以下步骤:
(1)在无菌室里,取利美索龙、枞酸、4-甲氧苯磺酰肼、痢特灵、酮康唑、兰索拉唑、黄杞苷、羧甲基纤维素钠、3-羟基-4-甲氧基苯甲酸、阿糖胞苷、β-谷甾醇、牛磺酸,依次加入非金属研钵中;每加入一种原料研匀3min,避光保存备用;
(2)将步骤(1)所得物、α变性淀粉放入水中,在50℃温度下搅拌15min;
(3)将步骤(2)所得物在45℃温度下压制成重量为0.8g的片剂;
(4)将片剂在-12℃温度下保存6h,即得成品。
对比例2
一种治疗干眼病的西药组合物,由以下重量份数的原料组成:利美索龙3份、黄杞苷0.8份、羧甲基纤维素钠3份、α变性淀粉7份、阿糖胞苷3份、枞酸0.7份、4-甲氧苯磺酰肼0.4份、痢特灵2份、酮康唑2份、齐墩果酸0.7份、3-羟基-4-甲氧基苯甲酸0.5份、β-谷甾醇0.5份、牛磺酸3份、水50份。
一种治疗干眼病的西药组合物的制备方法,其特征在于,包括以下步骤:
(1)在无菌室里,取利美索龙、枞酸、4-甲氧苯磺酰肼、痢特灵、酮康唑、齐墩果酸、黄杞苷、羧甲基纤维素钠、3-羟基-4-甲氧基苯甲酸、阿糖胞苷、β-谷甾醇、牛磺酸,依次加入非金属研钵中;每加入一种原料研匀3min,避光保存备用;
(2)将步骤(1)所得物、α变性淀粉放入水中,在50℃温度下搅拌15min;
(3)将步骤(2)所得物在45℃温度下压制成重量为0.8g的片剂;
(4)将片剂在-12℃温度下保存6h,即得成品。
对比例1中未添加齐墩果酸,对比例2中未添加兰索拉唑。
探究实施例1-3和对比例1-2制备的西药组合物治疗效果:
选择200名干眼病患者,其中,男110名,女90名,年龄15-60岁,实验时间长达6个月,具有统计学意义,且有代表性和可信度。
治疗方法:
将200名患者分为5组,每组40名,即实施例1组、实施例2组、实施例3组、对比例1组、对比例2组,实施例1组每日口服实施例1制备的西药组合物,实施例2组每日口服实施例2制备的西药组合物,实施例3组每日口服实施例3制备的西药组合物,对比例1组每日口服对比例1制备的西药组合物,对比例2组每日口服对比例2制备的西药组合物,一日两次,每次1g,早晚各一次,饭前半小时服用,两个月为1个疗程,治疗3个疗程。
疗效标准:
痊愈:眼睛干涩、疲倦、眼痒、有异物感、痛灼热感、分泌物黏稠、怕风、畏光、对外界刺激很敏感症状消失;眼睛红肿、充血症状消失;角质化、角膜上皮破皮而有丝状物黏附症状明显缓解。
有效:眼睛干涩、疲倦、眼痒、有异物感、痛灼热感、分泌物黏稠、怕风、畏光、对外界刺激很敏感症状消失;眼睛红肿、充血症状、角质化、角膜上皮破皮而有丝状物黏附症状明显缓解。
无效:治疗前后无变化或症状加深。
治疗结果见下表
表 实施例1-3和对比例1-2制备的西药组合物治疗效果
项目 | 例数/例 | 痊愈/例 | 有效/例 | 无效/例 | 有效率/% |
实施例1组 | 40 | 25 | 15 | 0 | 100 |
实施例2组 | 40 | 22 | 18 | 0 | 100 |
实施例3组 | 40 | 28 | 12 | 0 | 100 |
对比例1组 | 40 | 8 | 17 | 15 | 42.5 |
对比例2组 | 40 | 6 | 13 | 21 | 32.5 |
通过上表可以看出,实施例1-3通过添加齐墩果酸和兰索拉唑发生了协同作用,可有效治疗干眼病,有效率达100%,对眼睛干涩、疲倦、眼痒、有异物感、痛灼热感、分泌物黏稠、怕风、畏光、对外界刺激很敏感、眼睛红肿、充血、角质化、角膜上皮破皮而有丝状物黏附症状均有较好的疗效。治疗周期较短,且口感好,有利于患者坚持治疗;副作用小,能彻底根治,无并发症;制备方法简单,生产成本低,降低了人们的经济压力。
上面对本专利的较佳实施方式作了详细说明,但是本专利并不限于上述实施方式,在本领域的普通技术人员所具备的知识范围内,还可以在不脱离本专利宗旨的前提下做出各种变化。
Claims (6)
1.一种治疗干眼病的西药组合物,其特征在于,由以下重量份数的原料组成:利美索龙2-5份、黄杞苷0.2-2份、羧甲基纤维素钠2-5份、α变性淀粉5-10份、阿糖胞苷1-5份、枞酸0.5-1份、4-甲氧苯磺酰肼0.1-1份、痢特灵1-3份、酮康唑1-3份、齐墩果酸0.5-1份、兰索拉唑1-5份、3-羟基-4-甲氧基苯甲酸0.2-1份、β-谷甾醇0.1-1份、牛磺酸2-5份、水45-85份。
2.根据权利要求1所述的治疗干眼病的西药组合物,其特征在于,由以下重量份数的原料组成:利美索龙3份、黄杞苷0.8份、羧甲基纤维素钠3份、α变性淀粉7份、阿糖胞苷3份、枞酸0.7份、4-甲氧苯磺酰肼0.4份、痢特灵2份、酮康唑2份、齐墩果酸0.7份、兰索拉唑2份、3-羟基-4-甲氧基苯甲酸0.5份、β-谷甾醇0.5份、牛磺酸3份、水50份。
3.一种如权利要求1-2任一所述的治疗干眼病的西药组合物的制备方法,其特征在于,包括以下步骤:
(1)在无菌室里,取利美索龙、枞酸、4-甲氧苯磺酰肼、痢特灵、酮康唑、齐墩果酸、兰索拉唑、黄杞苷、羧甲基纤维素钠、3-羟基-4-甲氧基苯甲酸、阿糖胞苷、β-谷甾醇、牛磺酸,依次加入非金属研钵中;每加入一种原料研匀2-5min,避光保存备用;
(2)将步骤(1)所得物、α变性淀粉放入水中,在45-60℃温度下搅拌10-20min;
(3)将步骤(2)所得物在30-50℃温度下压制成重量为0.5-1g的片剂;
(4)将片剂在-15℃至-10℃温度下保存5-8h,即得成品。
4.根据权利要求3所述的治疗干眼病的西药组合物的制备方法,其特征在于,所述步骤(2)将步骤(1)所得物、α变性淀粉放入水中,在50℃温度下搅拌15min。
5.根据权利要求3所述的治疗干眼病的西药组合物的制备方法,其特征在于,所述步骤(3)将步骤(2)所得物在45℃温度下压制成重量为0.8g的片剂。
6.根据权利要求3所述的治疗干眼病的西药组合物的制备方法,其特征在于,所述步骤(4)将片剂在-12℃温度下保存6h,即得成品。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201611107165.4A CN106581035A (zh) | 2016-12-06 | 2016-12-06 | 一种治疗干眼病的西药组合物 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201611107165.4A CN106581035A (zh) | 2016-12-06 | 2016-12-06 | 一种治疗干眼病的西药组合物 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN106581035A true CN106581035A (zh) | 2017-04-26 |
Family
ID=58597153
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201611107165.4A Withdrawn CN106581035A (zh) | 2016-12-06 | 2016-12-06 | 一种治疗干眼病的西药组合物 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN106581035A (zh) |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1159323A (zh) * | 1995-11-15 | 1997-09-17 | 田边制药株式会社 | 用于防治干眼病或由其引起的疾病的药物组合物方法和装置 |
CN1732008A (zh) * | 2002-12-24 | 2006-02-08 | 爱尔康公司 | 利美索龙治疗干眼病的用途 |
CN1946352A (zh) * | 2004-04-09 | 2007-04-11 | 狄科特康坦特公司 | 递送药物至眼以治疗后段疾病的方法和物品 |
CN101980700A (zh) * | 2008-02-20 | 2011-02-23 | 密苏里大学董事会 | 包含奥美拉唑和兰索拉唑以及缓冲剂的组合的组合物及其使用方法 |
CN103156861A (zh) * | 2011-12-08 | 2013-06-19 | 陈丽梅 | 齐敦果酸衍生物及其可药用盐在治疗糖尿病眼病中的应用 |
CN106038603A (zh) * | 2016-06-26 | 2016-10-26 | 钟志敏 | 一种用于白内障术后并发纤维性葡萄膜炎的胶囊剂 |
-
2016
- 2016-12-06 CN CN201611107165.4A patent/CN106581035A/zh not_active Withdrawn
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1159323A (zh) * | 1995-11-15 | 1997-09-17 | 田边制药株式会社 | 用于防治干眼病或由其引起的疾病的药物组合物方法和装置 |
CN1732008A (zh) * | 2002-12-24 | 2006-02-08 | 爱尔康公司 | 利美索龙治疗干眼病的用途 |
CN1946352A (zh) * | 2004-04-09 | 2007-04-11 | 狄科特康坦特公司 | 递送药物至眼以治疗后段疾病的方法和物品 |
CN101980700A (zh) * | 2008-02-20 | 2011-02-23 | 密苏里大学董事会 | 包含奥美拉唑和兰索拉唑以及缓冲剂的组合的组合物及其使用方法 |
CN103156861A (zh) * | 2011-12-08 | 2013-06-19 | 陈丽梅 | 齐敦果酸衍生物及其可药用盐在治疗糖尿病眼病中的应用 |
CN106038603A (zh) * | 2016-06-26 | 2016-10-26 | 钟志敏 | 一种用于白内障术后并发纤维性葡萄膜炎的胶囊剂 |
Non-Patent Citations (2)
Title |
---|
彭清华等: ""近年来中医治疗干眼的研究进展"", 《中华中医药学刊》 * |
桂世瑞: ""损害眼睛的药物"", 《养生益寿指南》 * |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN109010761A (zh) | 一种缓解视疲劳和提高视力的眼部外用药及其制备方法 | |
CN106491962A (zh) | 一种用于眼部热疗的药物组合物及热疗明目眼贴和眼罩 | |
CN101874863B (zh) | 祛除疤痕的外用贴膏 | |
CN106581035A (zh) | 一种治疗干眼病的西药组合物 | |
CN106491892A (zh) | 一种治疗结膜炎的西药组合物 | |
CN106420797A (zh) | 一种治疗干眼病的西药组合及其制备方法 | |
CN104547736A (zh) | 一种治疗甲状腺肿的药物 | |
CN105663157A (zh) | 一种治疗火烧烫伤的药物及其制备方法 | |
CN101199766B (zh) | 一种治疗癫痫的药物 | |
CN101181448A (zh) | 治疗面瘫的口服中成药 | |
CN103263590B (zh) | 一种治疗面神经炎的中药外敷剂 | |
CN104096018A (zh) | 一种治疗面部神经麻痹症的中药组合物 | |
CN108378357A (zh) | 一种消除晚期肿瘤疼痛的食疗粉及其制备方法 | |
CN108114118A (zh) | 一种治疗偏头痛的穴位贴 | |
CN108434203A (zh) | 一种治疗鼻息肉的中药药膏及其制备方法和应用 | |
CN114948853B (zh) | 一种治疗周围性面瘫的中药外薰方及其制备方法和应用 | |
CN103830666B (zh) | 一种治疗高血压的中药足浴组合物 | |
CN102836178A (zh) | 一种治疗中耳炎的外用药物 | |
CN1144664A (zh) | 一种芳香保健乳罩药垫 | |
CN106267086A (zh) | 一种治疗原发性青光眼的中药制剂 | |
CN106214955A (zh) | 治疗高龄老人心脏衰竭的中药组合物 | |
CN106265678A (zh) | 一种用于治疗面瘫的膏药及其制备方法 | |
CN103893575B (zh) | 一种治疗白癜风的中药组合物及其制备方法 | |
CN103893706B (zh) | 一种治疗冠心病的中药制剂及制备方法 | |
CN101543552B (zh) | 一种治疗淋巴结肿大的中药制剂 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
WW01 | Invention patent application withdrawn after publication |
Application publication date: 20170426 |
|
WW01 | Invention patent application withdrawn after publication |